Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.

The article focuses on comparing the efficacy of venetoclax plus hypomethylating agents (VEN + HMA) versus intensive chemotherapy in treating acute myeloid leukemia with myelodysplasia-related gene mutations (AML-MR). Topics include the impact of genetic mutations on treatment decisions, the outcomes of VEN + HMA compared to standard chemotherapy, and the effects of different treatment regimens on overall and event-free survival rates in AML-MR patients.